Amgen is a drug manufacturers - general business based in the US. Amgen shares (AMGN) are listed on the NASDAQ and all prices are listed in US Dollars. Amgen employs 26,700 staff and has a trailing 12-month revenue of around $29.5 billion.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $309.38 |
|---|---|
| 52-week range | $211.82 - $326.12 |
| 50-day moving average | $298.99 |
| 200-day moving average | $284.66 |
| Wall St. target price | $318.72 |
| PE ratio | 44.8129 |
| Dividend yield | $8.64 (2.87%) |
| Earnings per share (TTM) | $7.00 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $309.38 from 2024-07-03
| 1 week (2024-06-27) | -1.37% |
|---|---|
| 1 month (2024-06-04) | 0.65% |
| 3 months (2024-04-04) | 15.40% |
| 6 months (2024-01-04) | 2.05% |
| 1 year (2023-07-03) | 37.50% |
|---|---|
| 2 years (2022-07-01) | 34.25% |
| 3 years (2021-07-02) | 24.40% |
| 5 years (2019-07-03) | 73.40% |
Valuing Amgen stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Amgen's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Amgen's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 45x. In other words, Amgen shares trade at around 45x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Amgen's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.3869. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Amgen's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Amgen's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $11.7 billion.
The EBITDA is a measure of a Amgen's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $29.5 billion |
|---|---|
| Operating margin TTM | 13.33% |
| Gross profit TTM | $19.9 billion |
| Return on assets TTM | 4.88% |
| Return on equity TTM | 72.57% |
| Profit margin | 12.74% |
| Book value | $9.36 |
| Market Capitalization | $168.3 billion |
TTM: trailing 12 months
Dividend payout ratio: 48.64% of net profits
Recently Amgen has paid out, on average, around 48.64% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.87% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Amgen shareholders could enjoy a 2.87% return on their shares, in the form of dividend payments. In Amgen's case, that would currently equate to about $8.64 per share.
While Amgen's payout ratio might seem fairly standard, it's worth remembering that Amgen may be investing much of the rest of its net profits in future growth.
Amgen's most recent dividend payout was on 6 June 2024. The latest dividend was paid out to all shareholders who bought their shares by 15 May 2024 (the "ex-dividend date").
Amgen's shares were split on a 2:1 basis on 21 November 1999. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Amgen shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Amgen shares which in turn could have impacted Amgen's share price.
Over the last 12 months, Amgen's shares have ranged in value from as little as $211.8219 up to $326.12. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Amgen's is 0.601. This would suggest that Amgen's shares are less volatile than average (for this exchange).
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
We analyzed a number of bitcoin ETFs to determine which are best to invest in.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Check out our picks of the best ETF brokers for beginners, options trading, micro-investing and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
Check out our picks of the best robo-advisors for new and experienced investors alike.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
Check out our picks of the best brokerage accounts for beginners, micro-investing, crypto trading and more.
There are many ways to invest and grow $50K depending on your financial situation, personal needs and goals.